Xuhua Lu

Prof. Dr. Xuhua Lu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
XXXia Xu
Xia Xu
YZYanbo Zeng
Yanbo Zeng
ZCZheng Chen
Zheng Chen
YYYang Yu
Yang Yu
HWHaibin Wang
Haibin Wang
Shige WangShige Wang
Shige Wang

30 May 2022 in Advanced Composites and Hybrid Materials
Verified
Journal Article
Closed access
PDF file
HLHang Liu
Hang Liu
HWHaibin Wang
Haibin Wang
XLXuhua Lu
Xuhua Lu
VMVignesh Murugadoss
Vignesh Murugadoss
MHMina Huang
Mina Huang
ZGZhanhu Guo
Zhanhu Guo

1 October 2021 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
ZCZheng Chen
Zheng Chen
HWHang Wu
Hang Wu
HWHaibin Wang
Haibin Wang
DZDionisio Zaldivar-Silva
Dionisio Zaldivar-Silva
LALissette Agüero
Lissette Agüero
Shige WangShige Wang
Shige Wang

1 January 2023 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
HMHongdao Ma
Hongdao Ma
CWChenfeng Wang
Chenfeng Wang
LHLin Han
Lin Han
FKFanqi Kong
Fanqi Kong
ZLZhixiao Liu
Zhixiao Liu
XLXuhua Lu
Xuhua Lu
Background: The JAK/STAT signaling pathway is the main inflammatory signal transduction pathway, whether JAK/STAT contributes the pathology of SCI and targeting the pathway will alleviate SCI needs to be addressed. Here, we explored the therapeutic effect of pan-JAK inhibitor tofacitinib (TOF) on secondary injury after SCI and explained the underlying mechanisms.

18 May 2024 in Chemical Engineering Journal
Verified
Journal Article
Closed access
LXLin Xu
Lin Xu
QLQisheng Li
Qisheng Li
HWHaibing Wang
Haibing Wang
HLHui Liu
Hui Liu
DYDeng-Guang Yu
Deng-Guang Yu
XLXuhua Lu
Xuhua Lu

16 April 2014 in BMC Genomics
Verified
Journal Article
Open access
PDF file
Xiao-Ou ZhangXiao-Ou Zhang
Xiao-Ou Zhang
QYQing-Fei Yin
Qing-Fei Yin
HWHai-Bin Wang
Hai-Bin Wang
YZYang Zhang
Yang Zhang
TCTian Chen
Tian Chen
LYLi Yang
Li Yang
Intron-derived long noncoding RNAs with snoRNA ends (sno-lncRNAs) are highly expressed from the imprinted Prader-Willi syndrome (PWS) region on human chromosome 15. However, sno-lncRNAs from other regions of the human genome or from other genomes have not yet been documented. By exploring non-polyadenylated transcriptomes from human, rhesus and mouse, we have systematically annotated sno-lncRNAs expressed in all three species. In total, using available data from a limited set of cell lines, 19 sno-lncRNAs have been identified with tissue- and species-specific expression patterns. Although primary sequence analysis revealed that snoRNAs themselves are conserved from human to mouse, sno-lncRNAs are not. PWS region sno-lncRNAs are highly expressed in human and rhesus monkey, but are undetectable in mouse. Importantly, the absence of PWS region sno-lncRNAs in mouse suggested a possible reason why current mouse models fail to fully recapitulate pathological features of human PWS. In addition, a RPL13A region sno-lncRNA was specifically revealed in mouse embryonic stem cells, and its snoRNA ends were reported to influence lipid metabolism. Interestingly, the RPL13A region sno-lncRNA is barely detectable in human. We further demonstrated that the formation of sno-lncRNAs is often associated with alternative splicing of exons within their parent genes, and species-specific alternative splicing leads to unique expression pattern of sno-lncRNAs in different animals. Comparative transcriptomes of non-polyadenylated RNAs among human, rhesus and mouse revealed that the expression of sno-lncRNAs is species-specific and that their processing is closely linked to alternative splicing of their parent genes. This study thus further demonstrates a complex regulatory network of coding and noncoding parts of the mammalian genome.